Media Overview
Boehringer Ingelheim’s hub for providing you with the latest press releases, news and further press material for download.
Press Releases
SPEVIGO® approved for expanded indications in China and the US
New partnership to develop schizophrenia treatments
Survodutide Phase II trial shows groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Newsbits
FDA grants breakthrough status to schizophrenia treatment
EU approves Jardiance® for treatment of type 2 diabetes in children aged 10 years and above
Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials
Media Contacts
Head of Global Media Relations
E-Mail:
harro.ten_wolde@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-181352
Senior Media Relations Manager
E-Mail:
tereza.urbankova@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-184817
Head of Human Pharma Communications
E-Mail:
anthonia.aboyeji@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-172370
Head of Animal Health Communications
E-Mail:
Heidi.DeWit-Sommerfeld@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-171799
Head of Innovation Unit Communications
E-Mail: camilla.krogh_lauritzen@boehringer-ingelheim.com
Phone Number: +45 2272 4806
Current Events
Annual Results Press Conference 2024
Past Events
Transforming Science Day: Europe Register Now!
Transforming Science Day
Annual Results Press Conference 2023
